small molecule

ISOVUE-250

IOPAMIDOL

Loss of exclusivityOctober 2028FDA regulatory exclusivity expiry
CompanyBRACCO DIAGNOSTICS INC

Drug detail

Brand nameISOVUE-250
Active ingredientIOPAMIDOL
Strength51%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 1992
Marketing statusRX

Regulatory exclusivity

CodeExpires
I-975October 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

ISOVUE-250 patent cliff — loss of exclusivity October 2028 | CliffBio